Thiazolidinediones in Type 2 Diabetes Mellitus
- 1 January 2003
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 63 (13) , 1373-1405
- https://doi.org/10.2165/00003495-200363130-00004
Abstract
Type 2 diabetes mellitus is characterised by insulin resistance as well as progressive pancreatic β cell dysfunction. The cornerstone of current oral blood-glucose lowering therapy consists of...Keywords
This publication has 103 references indexed in Scilit:
- Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery DiseaseCirculation, 2003
- Troglitazone and related compoundsLife Sciences, 2000
- PioglitazoneDrugs, 2000
- The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitusJournal of Clinical Investigation, 1999
- Troglitazone-Induced Heart and Adipose Tissue Cell Proliferation in MiceToxicologic Pathology, 1999
- RosiglitazoneDrugs, 1999
- Troglitazone in Combination With Sulfonylurea Restores Glycemic Control in Patients With Type 2 DiabetesDiabetes Care, 1998
- Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect.Journal of Clinical Investigation, 1995
- Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin ResistanceScience, 1993
- Early Metabolic Defects in Persons at Increased Risk for Non-Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1989